The March of Technology

Publication
Article
Oncology Live®Vol. 17/No. 5
Volume 17
Issue 5

The creation of new technology is a complicated, risky business regardless of the area of healthcare or industry. The cover story in this issue, “Proton Beam Centers Multiply Despite Economic Risks,” illustrates that the oncology field is no exception to those rules of the marketplace.

OncLive Chairman,

Mike Hennessy

The creation of new technology is a complicated, risky business regardless of the area of healthcare or industry. The cover story in this issue, “Proton Beam Centers Multiply Despite Economic Risks,” illustrates that the oncology field is no exception to those rules of the marketplace.

Proton therapy centers that cost at least tens of millions of dollars to build are under construction throughout the United States, even though experts remain divided over whether the technology is superior to conventional radiotherapy.

Intuitively, it would seem that radiation treatment that hits cancerous cells while sparing surrounding tissue would be far more tolerable and effective for patients. In practice, that theory has been difficult to prove in clinical trials. As a result, insurers are likely to approve proton therapy for patients with intracranial, ocular, or skull-based tumors but not for the prostate cancers that institutions were hoping would help pay for the facilities.

Unlike new drugs, medical technology can be introduced in the United States without evidence of superiority, one commentator noted. In a market-driven economy, cancer centers that build proton therapy facilities are taking an enormous financial risk.

How else can innovative technology advance? Undoubtedly, there are other economic models. However, patients and their families want the most advanced treatments that our best minds can serve up.

We cannot imagine being in the situation that parents of a 5-year-old boy in Great Britain faced when they decided to remove their son from a hospital without the doctor’s permission and travel to Prague for proton treatment. The therapy is not offered in the United Kingdom—but it probably will be by 2018 after the outcry over that incident. Two proton beam centers are now being planned.

Getting from here to there in healthcare quite often seems to be a messy business. We don’t pretend to have all the answers, but we certainly want to help raise the questions. Please let us know what you think about these matters and, as always, thank you for reading.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Michael Leung, PharmD, an expert on colorectal cancer
A panel of 4 experts on colorectal cancer